HIMS Stock Price Today (May 2026) — Hims & Hers Health, Inc. Analysis & Key Metrics 2026-05-22
Hims & Hers Health, Inc. (HIMS) is trading at $23.75, down 1.08% today (as of May 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $26.25 (10.5% upside).
- Volatility remains elevated (85.36% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (28.40% YoY) alongside significant competitive pressures.
HIMS Stock Analysis: Key Metrics & Valuation (May 2026)
Concise, actionable data for investors
Hims & Hers Health, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $6.79B
P/E Ratio
Forward P/E: 19.87
Revenue Growth
Year over Year
Analyst Target
+10.5% upside potential
Key Investor Questions About HIMS
What investors need to know before buying
Based on current market data, HIMS presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 43.20)
- Fundamentals say: Caution warranted (high leverage concerns)
HIMS's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for HIMS investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $1.12B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, HIMS stock traded between $13.74 and $70.43—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 85.36% annualized volatility and β=2.31, the stock exhibits high sensitivity to market moves—making HIMS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Hims & Hers Deepens Personalized Care Through Platform Expansion
HIMS broadens beyond telehealth, adding labs, new hormone programs and global expansion as it builds a personalized care platform.
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry
The launch follows Novo Nordisk’s failure to pay a C$250 patent maintenance fee in Canada.
The Silver Lining of Last Week's Hims & Hers Earnings Miss
Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.
Canadians can now get digital prescriptions for 'generic Ozempic'
Hims & Hers has started offering eligible customers personalized treatment plans starting at $149/month
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry
By Sriparna Roy May 21 (Reuters) - Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's
Live Longer and Better. Does Medicine’s New Obsession Really Work?
The longevity industry is booming with high-tech tests, drugs, and medical devices. What to know for your health—and personal finances.
5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings Call
Hims & Hers Health’s first quarter was marked by a significant strategic pivot in its weight loss business, which management described as a move to prioritize branded medications over compounded products. CEO Andrew Dudum highlighted that this shift resulted in near-term financial pressures, including restructuring charges and margin compression, as the company adapted to evolving consumer demand and regulatory developments. The company also experienced increased investment in technology and ope
Spotting Winners: Hims & Hers Health (NYSE:HIMS) And Healthcare Technology Stocks In Q1
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims & Hers Health (NYSE:HIMS) and its peers.
Is CAH Becoming the Backbone of US Healthcare Infrastructure?
Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure.
Hims & Hers Prices Upsized $350 Million Convertible Notes Offering
Hims & Hers increased its private offering from $300 million to support expansion, Eucalyptus acquisition plans, and technology investment.
Frequently Asked Questions
Common investor questions about Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (HIMS) is currently trading at $23.75. The RSI (14-day) is at 43.2, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $26.25 implies 10.5% upside from current levels. Volatility is high at 85.4% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Hims & Hers Health, Inc. (HIMS): The trailing P/E ratio is 53.75, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 19.87, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.36, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 11.52. Price-to-Sales is 2.70. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 14 analysts covering HIMS, the consensus price target is $26.25. This represents a 10.5% upside from the current price of $23.75. The range spans from a low target of $18.00 to a high target of $35.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Hims & Hers Health, Inc. (HIMS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Hims & Hers Health, Inc. (HIMS) investors include: 1. High volatility (85.4% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 207.16) which could pressure margins in a rising rate environment. 3. Elevated short interest (37.3% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Hims & Hers Health, Inc.'s (HIMS) current debt and financial health profile: Total debt stands at $1.12B. The debt-to-equity ratio is 207.16, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.90, indicating strong short-term liquidity. The quick ratio is 1.51. The company holds $577.49M in cash and equivalents. Free cash flow is positive at $110.51M, providing a cushion for debt servicing and shareholder returns.